{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-032815","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.829207+00:00","generated_at":"2026-05-31T16:36:10.374305+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis","bullets":["AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.","84% of participants maintained FVIII activity >5% at 15 months; mean treated ABR reduced 98.3% (0.07 vs 4.08, p<0.0001).","Sangamo eligible for up to $220M in regulatory/commercial milestones plus 14%-20% royalties on sales.","One participant (1.3%) returned to prophylaxis; treatment generally well tolerated with transient elevated FVIII in 49.3%.","Pfizer to discuss data with regulatory authorities; Sangamo's first potential commercial medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-032815","json":"https://secwatch.observer/filing/0001628280-24-032815.json","markdown":"https://secwatch.observer/filing/0001628280-24-032815.md","text":"https://secwatch.observer/filing/0001628280-24-032815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024032815/0001628280-24-032815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024032815/sgmo-20240724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:36:10.374305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}